New contract spotlight, Coloplast’s Biatain Silicone Fit expands US wound-care reach

Coloplast’s Biatain Silicone Fit foam dressings have secured an Innovative Technology contract with US group purchasing giant Vizient, boosting the advanced wound-care line’s visibility in hospitals and clinics. Here is what the product offers and why the deal matters.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 7:15 AM ET. Details in the imprint.

Biatain Silicone Fit, Coloplast’s latest silicone foam dressing line for complex and irregular wounds, has gained extra traction in the US after winning an Innovative Technology contract from major group purchasing organization Vizient. The deal gives hospitals and clinics in Vizient’s network access to the dressings under negotiated terms, potentially accelerating adoption in advanced wound care.

What Biatain Silicone Fit is designed to do

Biatain Silicone Fit is a family of soft, absorbent foam dressings with a gentle silicone adhesive, developed to manage exuding wounds such as pressure ulcers, diabetic foot ulcers and venous leg ulcers while conforming closely to uneven body areas. Coloplast describes the product as built to “fit” anatomically challenging sites like heels, sacrum and peri-wound areas, with flexible foam that molds to contours and helps maintain a moist healing environment. Coloplast’s official product page lists bordered silicone foam variants in multiple shapes and sizes, including standard, heel and sacral formats.

The dressings combine a polyurethane foam pad with a semi-permeable top film to manage moderate to high levels of exudate, aiming to reduce leakage and protect surrounding skin. According to Coloplast, the silicone contact layer is engineered for secure yet atraumatic adherence so the dressing can be repositioned during application and removed with less pain and skin stripping compared with traditional acrylic adhesives, which is particularly important for fragile geriatric skin and chronic wound patients. The range is indicated for a broad spectrum of wound types, including post-operative wounds and skin tears, making it a versatile option for multidisciplinary wound-care teams in both inpatient and outpatient settings.

Biatain Silicone Fit sits alongside existing Biatain Silicone dressings but emphasizes conformability and edge sealing on irregular surfaces, where poor fit can otherwise lead to exudate leakage and maceration. The product line is part of Coloplast’s chronic care and wound and skin care portfolio, a strategic area that the company has highlighted as a growth driver in recent investor presentations. In its 2024/25 financial communications, Coloplast pointed to advanced wound care as a focus segment, with product innovation and US penetration as key themes, and Biatain-branded silicone dressings feature prominently in its category overview. The company’s investor relations materials underline chronic care as one of the main revenue pillars and reference advanced dressings within that mix.

The Vizient Innovative Technology contract, announced in May 2026, recognizes Biatain Silicone Fit after evaluation by a member-led council that reviews new medical technologies for potential clinical benefit and operational value. Vizient stated that products granted this status are made available to its membership of more than 5,000 health-system members, including academic medical centers, community hospitals and non-acute facilities, through its contracting portfolio. In the contract announcement, Coloplast emphasized that the agreement does not guarantee volume but provides a structured pathway for Biatain Silicone Fit to be considered and trialed across a broad base of US providers, which can be especially impactful in formulary-driven categories such as wound dressings. The joint press release via GlobeNewswire notes that the contract was awarded following assessment under Vizient’s Innovative Technology program.

For Coloplast, Biatain Silicone Fit expands its footprint in the competitive advanced wound-care market, where silicone foam products from several multinational manufacturers compete on absorbency, conformability and patient comfort. The contract with Vizient broadens the product’s potential reach in the US and supports the company’s ambition to grow its wound and skin care franchise alongside its larger ostomy and continence care businesses. Shares of Coloplast A/S (ISIN DK0060448595) last traded on Nasdaq Copenhagen at DKK 400.20 on 06/14/2026.

Biatain Silicone Fit quick profile

• Product: Biatain Silicone Fit
• Manufacturer: Coloplast A/S
• Category: New Release / Launch - advanced wound dressing
• Launch date: 2024 (initial market introduction, with 2026 Vizient Innovative Technology contract in the US)
• MSRP / Price: Contract-based institutional pricing in the US; individual unit prices vary by size and configuration
• Availability: Advanced wound-care distributors and hospital purchasing in the US and selected international markets
• Target audience: Hospitals, clinics and wound-care specialists treating exuding acute and chronic wounds
• Key differentiator / USP: Silicone foam dressing designed to conform to irregular body areas and maintain a moist healing environment while aiming for gentle removal

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.